U.S. Department of Health and Human Services
Jeffrey Kopp
 

 Contact Info

 
Tel: +1 301 594 3403
Email: jeffreyk@mail.nih.gov
 

 Training and Experience

 
M.D., University of Pennsylvania Medical School, 1980

A.B., Harvard College, 1975

Senior Investigator, NIDDK, NIH, 1995-present

Consulting Nephrologist, Mark Hatfield Clinical Research Center, NIH, Present

Commissioned Officer (Captain) Active Member (Rapid Deployment Force Teams PHS 1), U.S. Public Health Service, Present

Adjunct Professor of Medicine, Uniformed Services University of the Health Sciences, Present

Medical Staff Fellow, NIH, 1987-1995

Completed training in Internal Medicine and Nephrology, University of Washington, 1987
 

 Related Links

 

Jeffrey B. Kopp, M.D.

Chief, Kidney Diseases Branch
Senior Investigator, Kidney Diseases BranchKidney Diseases Section
Specialties: Clinical Research, Genetics/Genomics, Health Disparities

Research Summary

Current Research

Dr. Kopp leads a translational research group within the Kidney Disease Section, Kidney Diseases Branch, studying focal segmental glomerulosclerosis (FSGS) and related podocyte diseases.

Recent highlights

  • Chromosome 22 harbors a major risk locus for kidney disease in African Americans, including FSGS, HIV-associated nephropathy, and arterionephroclerosis (hypertension-attributed kidney disease).  APOL1 coding variants, which protect against trypanosomal infection, are strongly associated with kidney disease (odds ratios 7-29).  The mechanism of glomerular injury is unknown.
  • The HIV-1 protein Vpr, expressed in the glomerular podocytes, is sufficient to reproduce the chief features of HIV-associated collapsing glomerulopathy in transgenic mice.

Current research efforts

  • determining the mechanisms by which Apol1 variants damage the glomerulus
  • examining whether cardiotrophin-like cytokine 1 is a permeability factor that contributes to recurrent FSGS following kidney transplant
  • an open label phase II trial examining the efficacy of rituximab combined with cyclosporine (for 48 weeks) for treatment of refractory podocyte disease
  • participating in the ORD-funded NEPTUNE study of nephrotic diseases

Information for patients

  • We are actively recruiting individuals with focal segmental glomerulosclerosis and those with undiagnosed nephrotic syndrome or proteinuria.
  • All NIH trials are listed at clinicaltrials.gov.
  • Information about glomerular diseases is available on the Clomerular Disease Primer page​.

Reagents available to the research community

Transgenic mice

  • Podocin promoter/rTTA (reverse tetracycline transactivator)—also available from JAX and as herozygotes or homozygotes
  • TRE (tet responsive element)/Vpr
  • Alb/TGF-beta mice (request permission from Dr. Snorri Thorgeirsson, NCI)
  • Antibodies
  • rabbit polyclonal antibody to Vpr1-50 peptide—also available from AIDS Research and Reference Reagent Program
  • rabbit antiserum to human podocin (cross-reactive with mouse podocin)
  • rabbit antiserum to human nephrin (no cross-reactivity with mouse nephrin)
  • goat antimouse mesangial cell serum, for induction of glomerulonephritis in mice

Podocyte cell lines

  • mouse podocytes, immortalized with thermosensitive SV40 T Ag and bearing podocin/rtTA, for expression of genes of interest in cultured mouse podocytes
  • same, plus TRE silencer to reduce background expression
  • human urine derived podocyte-like epithelial cells (HUPECs), immortalized with hTERT and thermosensitive SV40 T Ag

Please contact us for further details.  NIDDK MTAs are available through Technology Advancement and Transfer.​